236 Studies Now Enrolling
Menu
Search
Medical Condition
- Show all (1752)
- Addiction (19)
- Allergy, Asthma, & Immunology (13)
- All of Us Research Program - NIH (1)
- Autoimmune Disorders (29)
- Blood Disorders (33)
- Bone & Muscle (10)
- Cancer (564)
- Child Development (4)
- COVID-19 (Coronavirus) (36)
- Critical Illness (1)
- Diabetes (21)
- Ear, Nose and Throat (12)
- Endocrine & Metabolic Disease (12)
- Eye (7)
- Gastrointestinal and Digestive Diseases (26)
- (-) Hair and Skin Disorders (3)
- Headaches (5)
- Healthy Volunteers (187)
- Heart Disease (130)
- Infectious Disease (49)
- Insomnia (2)
- Kidney Disease (12)
- Liver Disease (53)
- Lung Disease (31)
- Meniere's Disease (1)
- Neurological Disorders (165)
- Nutrition (5)
- Obesity (10)
- Obstetrics & Gynecology (55)
- Pain Management (1)
- Pediatrics (103)
- Psychiatric Disorders (67)
- Rehabilitation (9)
- Stroke (7)
- Surgery (7)
- Transplant (48)
- Urology (4)
- Vascular Conditions (10)
Displaying 1 - 9 of 9
Condition: Hair and Skin Disorders
Investigator: Joshua Cook, MD, PhD
Status: Currently Recruiting
We are conducting a research study on how psoriasis might be caused or worsened by high levels of the blood sugar-lowering hormone insulin. We are seeking people with plaque psoriasis, ages 18-65, who are overweight or obese with a body mass index of 25-35. Participants will have blood drawn and small skin biopsies taken from psoriasis plaques and nearby…
Condition: Hair and Skin Disorders
Investigator: Angela Christiano, PhD
Status: Currently Recruiting
The purpose of this study is to examine the causes and pathology of alopecia areata and other hair and skin disorders. Skin biopsies and blood and/or clinical information collected in the study will be used for research aiming at developing new options for the treatment of alopecia areata and other skin and hair disorders.
Condition: Hair and Skin Disorders
Investigator: Lynn Petukhova, PhD
Status: Closed
Genetic studies help us to understand why some people develop certain diseases while others don't and also provide important clues about how best to treat the disease.
Condition: Endocrine & Metabolic Disease / Cushing's Disease
Investigator: Pamela Freda, MD
Status: Closed
This study is for individuals who have Cushings disease and want to join voluntarily in this study to find out if a study drug called osilodrostat (LCI699) is safe and has beneficial effects in people who have Cushings disease. Cushings disease is a rare but debilitating disease. Cushings disease is caused by a benign tumor of the pituitary gland. The tumor…
Condition: Endocrine & Metabolic Disease / Cushing's Disease
Investigator: Amanda Tsang
Status: Closed
The purpose of this study is to determine if measuring blood levels of proteins called POMC, AgRP, and chromogrannin A (CGA) can be used to diagnose and track tumor growth and recurrence in patients that have ACTH-dependent Cushing's syndrome, non-secreting pituitary tumors, and other neuroendocrine tumors. We invite you to participate if you have: a…
Condition: Psychiatric Disorders / PTSD
Investigator: Franklin Schneier, MD
Status: Closed
We are currently enrolling individuals with post-traumatic stress disorder (PTSD) to participate in this research study. The purpose of this research study is to evaluate the effectiveness of an investigational medication, brexpiprazole, for PTSD. Eligible participants will be randomly assigned to receive either brexpiprazole, sertraline (also known as…
Condition: Psychiatric Disorders / PTSD
Investigator: Yuval Neria, PhD
Status: Closed
Approximately half of the individuals with Post-traumatic Stress Disorder (PTSD) present with major depressive disorder (MDD). Compared to PTSD alone, patients with comorbid PTSD-MDD demonstrate greater distress and poorer treatment outcome. The goal of this pilot study is to collect preliminary data on the feasibility, safety, and initial efficacy of an…
Condition: Endocrine & Metabolic Disease / Cushing's Disease
Investigator: Pamela Freda, MD
Status: Closed
The purpose of this study is to confirm the effectiveness and safety of LCI699 in treating patients with Cushing's disease. Patients will be treated with the invesitigational drug LCI699 at doses up to 60 mg a day, and possibly for a short period of time with placebo. A placebo is a dummy drug ("pill") with no active medicine inside.
Condition: Psychiatric Disorders / PTSD
Investigator: Yuval Neria, PhD
Status: Closed
Emerging research has demonstrated a relationship between visual attention patterns and anxiety disorders, including PTSD. This study is designed to examine these visual attention patterns using eye-tracking A simple device that monitors eye-movements. The study included two sessions conducted approximately 1 week apart, each no longer than 1 hour. In both…